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ABSTRACT 
 
Hydrogel particles encapsulating biomolecules or living cells are becoming 
an attractive means to mediate drug delivery or facilitate cell-based treatment of 
diseases. These particles are capable of maintaining drug stability/cell viability 
and providing specific drug release profiles. The selection of specific hydrogel 
and particle size depends on the administration routes, properties of the 
therapeutics and desired release profiles, and dictates the fabrication methods. 
We have chosen to design and fabricate hydrogel particles as a means to 
improve the efficacy of drug delivery utilizing mechanical, hydrodynamic and 
electric forces (precision particle fabrication (PPF) method and its modified 
scheme). Using such precision particles, we studied the drug release 
mechanisms that may help improve the design of new drug delivery vehicles. 
Monodisperse gelatin microspheres, fabricated via the electric field assisted 
PPF method, allowed detailed analysis of drug release without uncertainties 
ascribable to nonuniform particles. The results from this analysis, including zeta 
potential, particle swelling ratio, and intraparticle drug distributions, led to a 
release model, based on the reaction-diffusion and Michaelis-Menten kinetics. 
This model elucidates the effect of glutaraldehyde, a cross-linking agent, on 
release profile in terms of the initial drug distribution, diffusivity, degradation rate 
of gelatin and its ability to form polyionic complex with the drug. By measuring 
the drug diffusion constant and initial intrapaticle drug distribution in advance, the 
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model can predict the drug release and serve as a design tool for certain drug 
delivery scenarios. 
Hydrogel particles with peptide coating were developed as a vehicle for 
targeted delivery. The proposed drug delivery vehicle contains three main 
components: (1) anticancer drug, (2) targeting peptide, and (3) drug carrier. In 
this study, the peptide was used to target Cathepsin D that is overexpressed by 
breast cancer cells. Gelatin microspheres were utilized as drug carriers which 
immobilized doxorubicin, an anticancer drug. Uniform gelatin particles (30 µm in 
diameter, dry) were fabricated via the electric field assisted PPF method to 
optimize the drug loading efficiency. The particles suitable for intravenous 
injection (<10 µm, dry) were fabricated by increasing the electric field strength. 
The results of the release study and chemotherapy on cancer cells, performed in 
collaboration with Prof. Logan Liu’s group, confirmed that the use of peptide 
coating as a targeting moiety substantially enhanced the efficacy of 
chemotherapy, which would alleviate the adverse effect of chemotherapy 
ascribable to systemic distribution of chemotherapeutics. 
Alginate microspheres/microcapsules of precisely controlled size and size 
distribution were employed for cell encapsulation which could be utilized in cell-
based therapy and artificial organs. Cell viability was shown to remain intact after 
the encapsulation. The cross-linking of alginate with calcium ion involved the 
motion of both alginate molecules and calcium ions. The observation of 
significant size shrinkage from alginate microdroplets to microspheres indicated a 
junction-zone mode of the cross-linking process. A particle sorting scheme 
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combining optical detection and electric deflection was developed to deflect out 
capsules empty of cells and increase the yield in cell encapsulation. This may 
contribute to reducing the volume of microcapsules required for transplantation 
and make clinical application more practical. 
In summary, we have demonstrated the flexibility and practicality of the 
modified PPF method in producing precision hydrogel particles and the suitability 
of these particles for applications involving their applications for controlled drug 
delivery and tissue engineering. 
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CHAPTER 1 
INTRODUCTION 
 
1.1      Hydrogel in drug delivery and tissue engineering 
Progress in biotechnology has facilitated the discovery of new 
therapeutics involving peptides, proteins, cells and other potent/fragile drugs. For 
example, there are more than 40 marketed peptides or proteins worldwide 
including insulin, vancomycin, oxytocin and cyclosporine [1-4]. Cell-based 
therapies, utilizing artificial organs and delivery of genetically engineered cells, 
have been investigated for the past decades, and some are currently undergoing 
clinical trials [5]. While more understanding of pharmaceutics is established 
providing new hopes of cures for many currently untreatable diseases, 
achievement of high efficacy in the delivery of the pharmaceutics still has room 
for much improvement. 
Polymeric particles have attracted considerable attention in controlled 
drug delivery due to their stability, versatility for surface modification [6,7] and 
potential for achieving different drug release characteristics [8-10]. These 
delivery vehicles could provide long-term drug delivery, resulting in less frequent 
administration, which is a key to successful therapy for brain traumata or 
diseases in which multiple doses might not be feasible, thus reducing necrosis 
induced by repeated injection. The polymeric particles could also be modified on 
the surface so that the drug release may be triggered at the specific sites or in 
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certain environments [6,7] thus preventing systemic distribution of therapeutics. 
In addition to applications involving drug delivery, recent research also reported 
the use of polymeric particles as a means for providing immunoprotection for the 
transplanted cells [11], establishing a specific tissue culture microenvironment 
regulating stem cell differentiation [12,13] or increasing the viability of cultured 
cells [14]. Of various polymers, natural hydrogels have demonstrated excellent 
compatibility with tissue, good control of solute permeability, ability to be injected 
directly into the affected areas [15,16] and non-toxic or mildly toxic processing 
conditions, which maintain the functionality of biomolecules or viability of 
encapsulated cells.  
Particle size control has several important implications for controlled drug 
delivery and cell encapsulation such as drug release rate and viability of 
encapsulated cells [14]. The rate of drug diffusion and degradation of the polymer 
matrix strongly depends on the surface-to-volume ratio of the particles, which is a 
function of particle size. Besides, the biodistribution of the particles inside the 
body is influenced by their size. Rigid particles with a diameter of 6-10 µm were 
reported to be trapped in lungs (more than 84%), whereas the majority of those 
with a diameter less than 4 µm were found in the reticuloendothelial system (RES) 
[17]. Also, particles of 100-1200 nm in diameter might be used for cancer-
targeting delivery via the enhanced permeability and retention (EPR) effect 
ascribable to the loose structure of tumor microvessels. Therefore, a desired 
drug release behavior which depends on drug release rate and biodistribution of 
drug carrier cannot be achieved without controlled particle size and size 
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distribution. Besides, investigation of processing parameters on drug release 
behavior could not be achieved either because of uncertainty due to the wide 
size distribution of particles. In tissue engineering, the optimal size of 
microcapsules encapsulating cells varies. For example, Dufrane et al. showed 
that pig islets in alginate microcapsules of 635 µm in diameter survive up to six 
months after transplantation without immunosuppression [18]. On the other hand, 
it was suggested that hepatocytes in the center of alginate microcapsules larger 
than 400 µm might not maintain their viablity due to limited diffusion of oxygen 
and nutrients [19]. Dying cells not only provide no therapeutic effects but might 
also cause adverse effects such as inflammatory responses. Besides, size 
reduction in capsules usually increases the percentage of inadequately 
encapsulated cell aggregates while islet cell aggregates show superior survival 
and functionality [20]. Therefore, fabrication of particles in controlled size and 
size distribution is crucial for both drug delivery and cell encapsulation. 
In the next section, we will review some of the most significant types of 
protocols for fabricating hydrogel particles.  
 
1.2      Fabrication of hydrogel-based particles 
Within the past decades, a multitude of protocols have been developed 
and reported, using synthetic or natural hydrogels to fabricate biopolymeric 
particles for drug delivery and cell encapsulation. Here the fundamentals of 
emulsion, desolvation, mechanical vibration, spray drying and co-axial air jet 
methods are reviewed. 
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1.2.1  Emulsion  
Emulsion method has been utilized for fabrication of polymeric particles 
from different materials. Hydrogel particles can be produced using simple water-
in-oil emulsion. Despite a multitude of emulsion techniques described in the 
literature, all of them suffer from certain shortcomings, such as low yields (<30%) 
or broad size distributions probably due to the lack of effective emulsifiers or 
surfactants. In addition, high energetic methods such as ultrasound, high-
pressure or high-speed homogenization have to be applied to achieve adequate 
particles sizes. These apparatus are expensive and the process might lead to 
denature of materials because of the heat generated during the process. 
Furthermore, purification to remove the toxic organic phase and remaining 
emulsifier is usually complex and tedious. Finally, the use of toxic organic phase 
or emulsifier makes this method inadequate for encapsulation of biomolecules or 
living cells. 
 
1.2.2  Desolvation  
Desolvation is a process of removal or dissociation of the solvent from a 
solution which is commonly used to purify or concentrate biomolecules such as 
DNA, RNA, proteins and polysaccharides from an aqueous solution. The main 
concept for such desolvation methods, sometimes referred to as precipitation, is 
to reduce the solubility of the solute in the solvent which can be achieved by 
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addition of neutral salt as salting-out agents [21], hydrophilic polymers such as 
dextran or polyethylene glycol [22] or miscible organic solvents [23], and by 
adjustment of the solution pH to the isoelectric point of the material [24]. The 
desolvation method is appropriate for the preparation of particles composed of 
charged polymer with a defined molecular weight. However, for natural polymer 
with a wide range of molecular weight the method lacks reproducibility and 
homogeneity of the resulting particles. The obstacle might be resolved by 
eliminating the lower molecular weight fraction before the precipitation of 
particles, which leads to homogeneity of the particles [25]. Still, current protocols 
lack size control of particles and generally result in hydrogel particles smaller 
than 1 µm which significantly increase the drug release rate due to their high 
surface-to-volume ratio. 
 
1.2.3  Mechanical vibration 
Mechanical vibration on solution jet has been utilized to fabricate particles 
of different sizes. Lord Rayleigh first found that the most unstable disturbance 
wave imposed on a jet surface resulted in the break-up of the jet into uniform 
droplets. With the wave of an optimal wavelength, droplet radius is typically 1.9 
times the jet radius. Although disturbance of other wavelengths might produce 
uniform droplets, jet size and therefore nozzle opening are still the limiting factors 
in producing small particles. The precision particle fabrication method developed 
by Kim et al. has been applied to resolve the above problems and to fabricate 
polymeric particles of sizes much smaller than the nozzle opening. During the 
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process, polymer solution forms a jet of a diameter smaller than the nozzle 
opening due to the hydrodynamic forces of the surrounding immiscible solution. 
The jet is further broken into uniform droplets by mechanical forces and the 
droplets become uniform particles after drying. The concurrent use of mechanical 
and hydrodynamic forces allows this method to be less limited by nozzle 
dimension or solution viscosity. Sizes of hydrogel particles are still confined to 
micro scales, usually larger than 50 µm after swelling when administered into 
living tissue, because of jet instability, especially when the jet diameter goes 
below 20 µm. 
 
1.2.4  Spray drying  
Spray drying is a method of producing dry powders from a solution via 
three processing stages: atomization, evaporation in air and collection of dry 
product from the exit air [26]. Atomization determines the size and size 
distribution of the particles, which are the single most crucial factor in the process. 
The droplet size establishes the available heat transfer surface area, and thus 
the drying chamber design is influenced by the choice of atomizer. Spray drying 
provides effective control of product properties and quality, and high production 
rate in continuous operation, and is thus suitable for heat-sensitive materials. 
Among all atomization techniques, electrospray might be the most important 
technology; it employs high voltage to disperse the solution, which is supplied 
through a nozzle. Various waves on the surface of the jet lead to the formation of 
droplets which are subsequently dispersed due to Coulomb repulsion. Particle 
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size resulting from electrospray of aqueous solution is usually greater than a few 
hundred micrometers possibly due to the high conductivity of water.  
 
1.2.5  Coaxial air jet  
Coaxial air jet systems have been intensively studied for cell 
encapsulation; these systems employ an air jet around the solution jet to 
increase the force acting on nascent droplets. This method produces uniform 
droplets ranging from one millimeter to a few hundred micrometers. However, the 
system usually requires limited flow rate, less than 30 mL/hour, to avoid 
formation of a liquid jet. Also, the size distribution broadens when the droplet 
diameter decreases or solution viscosity increases. Because the system cannot 
handle viscous solutions, thus-produced microcapsules are usually coated with 
polycation to reduce the pore size and to provide immunoprotection for the 
encapsulated cells, but the coating might not be biocompatible [27]. For these 
reasons, the coaxial systems have not been considered suitable for scale-up. 
 
1.3     Overview 
In this study, we fabricated particles of natural hydrogel polymers and 
studied the feasibility of employing these particles for applications involving 
controlled drug delivery and tissue engineering. 
Described In Chapter 2 is the electric field assisted precision particle 
fabrication (E-PPF) method that we utilized to fabricate monodisperse gelatin 
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microspheres (GMS) and to study parameters affecting the drug release from the 
basic gelatin which is a common carrier for protein, peptide or gene due to its 
ability to form polyionic complex with opposite-charged biomolecules. Uniformity 
of the GMS allowed us to study the drug release behavior without uncertainty 
resulting from wide size distribution. Specifically, we addressed the effects of the 
cross-linker, glutaraldehyde (GA), on drug release behavior, drug distribution 
within polymer matrix, polymer degradation, and the matrix ability to form 
polyionic complex with the drug. This information allowed the development of a 
mathematical model to predict the release of water soluble agents from cross-
linked GMS.  
Chapter 3 describes cancer-targeting delivery of chemotherapeutics via 
surface modified gelatin particles fabricated via the E-PPF method in an effort to 
increase the efficacy of chemotherapy. Also, an improved feature of the E-PPF 
apparatus that is particularly suited to fabricate sub-micron sized hydrogel 
microspheres is outlined.  
Chapter 4 outlines a capsule generator utilizing mechanical vibration to 
break coaxial jets. Also described is a feature designed to sort out empty 
capsules in the case of cell encapsulation, which is necessary to minimize the 
volume of the capsules be transplanted. The cross-linking of the alginate capsule 
was studied by monitoring the penetration of the calcium ion and measuring the 
intraparticle distribution of alginate.  
Conclusions and future work are described in Chapter 5. 
 
  9 
 
 
CHAPTER 2 
DRUG RELEASE PROFILE AND ITS MODELING FOR UNIFORM 
BASIC GELATIN MICROSPHERES UNDER DIFFERENT CROSS-LINKING 
DENSITIES 
 
2.1     Introduction 
Gelatin has attracted much attention in many biomedical applications 
because of its excellent biocompatibility and its degradability to non-toxic 
products [28,29]. The isoelectric point of gelatin derived from collagen can be 
modified during fabrication [30]. This unique aspect allows one to design and 
form a polyionic complex between a charged biomolecule and a gelatin of the 
opposite charge. For these reasons, gelatin is commonly utilized in tissue 
engineering and gene therapy [31-35]. For example, the release profiles of 125I-
labeled basic fibroblast growth factor (bFGF), transforming growth factor-β1 
(TGF-β1), bone morphogenetic protein-2 (BMP-2) and vascular endothelial 
growth factor (VEGF) [33,35] from acidic or basic gelatin in disk or microparticle 
forms have been studied. Gelatin microparticles were also employed to increase 
the transfection probability at the delivery site by the controlled release of 
plasmid DNA in vivo [34]. In spite of extensive applications reported, little 
comprehensive quantitative analysis has been available to date, which could be 
used for predicting and designing the release profiles of gelatin microparticles as  
drug carriers. 
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Mathematical modeling is important to systematically explore and design 
potentially new devices for controlled release [9]. In general, release of a water 
soluble active agent from degradable matrix devices is determined by a 
reciprocal action of the following processes [36]: (a) diffusion of the external 
aqueous medium into the device, (b) relaxation of the polymer matrix, including 
swelling, (c) liberation of the immobilized active agent due to hydrolytic or 
enzymatic degradation of the matrix, (d) diffusion of the mobile active agent from 
the bulk of the matrix to its surface, and (e) diffusion across the boundary layer. 
These processes are interrelated, which makes general mathematical modeling a 
formidable task. Mladenovska et al. assumed a biexponential function for the 
release from hydrogel devices based on the frequently-observed biphase release 
pattern for hydrogel [37]. Although the presumed biexponential function does 
simplify the mathematical formulation, the fundamental mechanisms responsible 
for the biphasic release pattern have not been elucidated. It is also known that 
not all the release profiles follow the biphasic pattern [38,39]. As a result, 
phenomenological models which account for only the release-limiting factors 
have been developed. 
Swelling or hydration has often been considered to predict the release 
from hydrogel devices. In this case the resulting models depend on the swelling 
interface number [15], wS , which is empirically adjusted for the release process 
[40,41]. Attempts were also made to take into account viscoelastic response and 
diffusion during polymer swelling [42]. Although some of these models produced 
results in agreement with experimental data, they required many adjustable 
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parameters [43]. Recently, a unified mathematical model was proposed to predict 
drug release from surface and bulk eroding hydrolyzable polymer matrices with 
all parameters obtained prior to the controlled release experiments [44]. The 
model, however, was limited to polyester and polyanhydride due to the specific 
assumption of the polymer degradation kinetics and exclusion of the enzymatic 
effect in the model. Tzafriri [36] reported a drug release model from polymer 
matrices entirely or partially due to the enzymatic polymer degradation, but no 
effects of cross-linker concentrations were included in the model. Therefore, to 
the best of our knowledge, no mathematical model proposed to date is suitable to 
predict drug release from gelatin microspheres (GMS) while accounting for the 
processing parameters. 
Herein, we propose a mathematical model to account for the release of a 
water-soluble active agent from uniform GMS, incorporating polymer degradation 
and specific drug distribution as a function of the cross-linking agent 
concentration. Specifically, the current model combines a diffusion-reaction 
equation, which accounts for the polyionic complexation between the drug and 
gelatin matrix, with polymer degradation and drug distribution dictated by the 
cross-linking agent concentration. Basic GMS of 100-µm diameter (wet) were 
used for the study. The effective diffusivities were determined by fitting Fick’s 
diffusion model to in vitro release of trypan blue, an acidic model drug, from GMS 
in the absence of collagenase. The relationship between the enzymatic 
degradation rate of GMS and the concentration of glutaraldehyde (GA), a cross-
linking agent, was obtained by fitting the proposed model to the in vitro release 
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data from GMS cross-linked with the GA concentrations of 0.125%, 0.375% and 
0.875% v/v in phosphate buffered saline solution in the presence of collagenase. 
The obtained degradation parameter was then used for the present model to 
predict the release of trypan blue from GMS cross-linked with GA concentrations 
of 0.25% and 0.625% v/v. 
 
2.2     Materials and methods 
2.2.1  Materials 
Basic gelatin (IEP=9.0, Mw=100kDa) was provided by Nitta Gelatin Co., 
Osaka, Japan. Span 85 (Sigma–Aldrich), hexane (Fluka), acetone (Sigma–
Aldrich), canola oil (Schnucks), 25% glutaraldehyde (GTA) (Sigma–Aldrich), 
trypan blue (Sigma–Aldrich) and phosphate buffered saline (PBS) (Sigma-Aldrich) 
and collagenase 1A (Sigma-Aldrich) were purchased from Sigma-Aldrich, USA. 
Alexa fluor 430 was purchased from Invitrogen. All materials were used as 
obtained.  
 
2.2.2  Preparation of microspheres 
GMS were prepared using electric field assisted precision particle 
fabrication method (E-PPF). Briefly, gelatin was dissolved in warm DI water (50-
60 oC) to make a 5% w/v solution which passed through an inner nozzle 
concentric with an outer nozzle carrying a liquid stream immiscible with the 
gelatin solution. The setup was applied with mechanical vibration using an 
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ultrasonic transducer (Branson Ultrasonic) controlled by a function generator 
(Hewlett Packard, Model 3225A). The disturbance caused the polymer stream to 
break up into uniform droplets, which were collected in a cold mixture of oil, 
hexane and span 85 (2-6 oC) to expedite the gellation process. The gelled GMS 
were then treated with acetone, centrifuged, and dried in a lyophilizer (Labconco, 
freezone 4.5 L) for a day.  
 
2.2.3  Cross-linked gelatin microspheres 
The GMS were cross-linked with glutaraldehyde (GA) using a method 
reported by Tabata et al. [45] with some modification. Briefly, the dry spheres 
were dispersed in a desired concentration of GA solution of pH 5 at 4 oC for 24 
hours, transferred to a glycine solution at room temperature to deactivate the 
remaining GA [45]. The resulting spheres were then washed with DI water and 
lyophilized.  
 
2.2.4  Drug impregnation 
An aqueous solution containing the drug (0.1% w/v of trypan blue or Alexa 
fluor) was dropped into a known amount of GMS (5 µl/mg) and left for two hours. 
The drug solution was completely absorbed into the GMS because the volume of 
the drug-containing solution was less than the theoretical swelling volume of 
GMS. 
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2.2.5  Characterization 
GMS were observed under optical microscopy and scanning electron 
microscope (Hitachi 4700) for morphology and sphericity. Uniformity of GMS was 
investigated by measuring the size of 50 particles. 
Cross-linked GMS were weighted in air-dry conditions and then immersed 
in phosphate buffer saline (PBS, pH 7.4) at room temperature for 24 hours and 
their wet weight was measured. The swelling ratio of cross-linked GMS was 
defined as the weight increase after swelling divided by the weight of dry GMS. 
The gelatin solution (5% w/v) was cross-linked under different GA 
concentrations (0.125, 0.25, 0.375, 0.625, and 0.875 % v/v) at 50 °C for 5 hours. 
The resulting solutions were rapidly cooled to –50 °C and lyophilized. The cross-
linked gelatin was ground into small particles and then suspended in PBS (pH= 
7.4) after filtration (5-µm pore). The zeta-potential of the suspension was 
measured five times using Malvern Zetasizer 3000. 
The intraparticle drug distribution of Alexa Fluor 430, investigated as a 
function of cross-linker concentrations, was obtained by measuring the 
fluorescence intensity distribution at the equatorial cross-section of the GMS 
using a confocal laser scanning microscope (CLSM, Olympus Fluoview FV 300 
Laser Scanning Biologic Microscope). The drug distribution was measured, 
immediately after loading and after 15 days to remove all mobile drug with PBS, 
to account for the total and the ionically-complexed drug, respectively [46].  
The images obtained were converted into intensity plots and radial 
distributions by averaging the intensity at a given radial distance from the GMS 
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center. The resulting intensity plots were linearly fitted and normalized so that the 
drug amount inside the microsphere corresponded to the amount observed in the 
release experiment. The distribution of mobile drug was assessed by subtracting 
the distribution of the ‘complexed drug’ from the initial drug distribution. 
 
2.2.6  In vitro drug release  
The drug-loaded GMS were incubated in two release media, prepared 
using phosphate buffered saline (PBS) with and without an enzyme (collagenase 
1A, 373 ng/ml), at 37 °C for 18 days with continuous agitation. The supernatant 
was sampled at scheduled time intervals and its optical absorption was 
measured spectrophotometrically using Gilford Response Spectrometer.  
 
2.3     Theory and mathematical models  
2.3.1  Release paradigm and case definition 
During the process of loading a finite amount of drug via hydration of the 
polymer matrix, drug molecules move inwards by diffusion and capillary forces, 
forming a polyionic complex with gelatin or remaining free inside the microsphere 
[39]. If the amount of the drug loading is in excess of that, gelatin can immobilize; 
this loading process results in two pools of drugs encapsulated in the 
microspheres: ‘mobile drug’ which is free to diffuse and ‘complexed drug’ which 
is immobilized by the gelatin matrix and released only upon matrix degradation. 
The determinants of the initial distribution of mobile and complexed drug include 
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the cross-linking agent concentration, the microsphere size, and the isoelectric 
point of gelatin. In the present model, we incorporated the initial distribution of 
mobile or complexed drug obtained from the fluorescence intensity distribution of 
drug at the equatorial cross-section of the GMS. By doing so, we introduced in 
the model the heterogeneous immobilizing strength of cross-linked GMS. 
When dispersing GMS in a buffer solution, water or buffer solution begins 
to hydrate the matrix and mobile drug starts to diffuse out while complexed drug 
remains stationary within the microspheres. Hydration in GMS can be assumed 
not to be a rate-limiting process and to be negligible because it is much faster 
than the release. The matrix geometry could also be assumed to remain 
unchanged during the release process because of the fast hydration. This 
assumption of invariant geometry is likely to hold since gelatin degradation is a 
bulk degradation process [47]. In addition, it can be assumed that the surface of 
the microspheres is most resistant to erosion and that the sphere remains the 
same size until most of the drug has been released, which is valid for most cross-
linked gelatin where the cross-linker is introduced from outside via absorption 
[46]. 
With the gelatin degradation catalyzed by collagenase, both mobile and 
complexed drug are released. The degradation depends on both the cross-
linking density of gelatin and the enzyme activity. A single diffusion coefficient 
was used in the model with which we implicitly assumed that the degradation-
liberated drug behaved similarly to the mobile drug and that the heterogeneous 
cross-linking density within the GMS introduces negligible changes in diffusivity 
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throughout the microsphere. This was justified by the fact that the diffusivity 
increased only 1.5 times in our experiment when the cross-linking agent 
concentration increased sevenfold. The diffusion coefficient was also 
hypothesized to be time-invariant during the particle degradation. This 
assumption is valid if most of the drugs are released prior to disintegration of 
GMS or significant matrix degradation leading to nearly invariant polymer density. 
 
2.3.2  Model development 
The release of the drug is assumed to be governed by a diffusion-reaction 
equation with a source term due to the liberation of the complexed drug initially 
immobilized in polymer matrix via the polyionic attraction between the drug and 
the polymer. Consider a spherical shell at a radial distance r  where the 
concentration of the diffusing substance is C  and the mobile substance 
generating in the element is sC  as shown in Figure 2.1. Assume the diffusion is 
isotropic along the radius, and the equation describing the release can be 
obtained: 
 
                                       
2
2
1 ( ) sCC CDr
t r r r t
∂∂ ∂ ∂ 
= + ∂ ∂ ∂ ∂ 
                                       (2.1) 
 
where D  is the diffusion coefficient of the drug through the polymer matrix. The 
equation is solved using the following boundary conditions: 
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where R  is the radius of the GMS. The boundary condition, Equation (2.3), 
arises from the assumption of an infinite sink: that is, the rate at which the drug 
diffuses to the surface of the microsphere equals the rate at which the drug 
leaves the microsphere. Hence there is no accumulation of the drug on the 
surface [48]. 
The diffusion constants could be obtained by modeling the first three-day 
release profiles from GMS in PBS solution without enzymatic degradation of 
polymer matrix. In this case, the second term on the right-hand side of Equation 
(2.1) becomes zero. The initial condition for this case is 
 
                                                      00( ) ( )mtC r C r= =                                             (2.4) 
 
where 0[ ( )]mC r  is the initial distribution of the mobile drug. This drug distribution 
within GMS was obtained as described in section 2.4. 
In drug release accompanying polymer degradation, the liberation rate of 
the complexed drug in the gelatin spheres participating in the diffusion process is 
associated with enzymatic polymer degradation mechanism. In general, 
enzymatically-catalyzed polymer degradation can be described by the Michaelis-
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Menten equation [36,49,50] as shown in Equations (2.5)-(2.7) where MK  
represents the Michaelis-Menten constant, k  kinetic parameter, E  enzyme, S  
polymer and P  final product. Usually maxV  and MK  are constants for a given 
enzyme-substrate pair. 
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It has been known that collagenase is efficient in catalyzing hydrolysis of 
collagen with 2 Mk K up to 106 M-1S-1 [51], when the most efficient enzyme is 
defined with 2 Mk K  in a range of 108-1010 M-1S-1 (perfect enzyme) [52]. Since 
gelatin is more susceptible to degradation than collagen, we assume that 
collagenase catalyzes a reaction each time the enzyme molecule encounters 
gelatin molecule and that an upper theoretical limit has thus been reached for the 
efficiency, which suggests the limit [ ] MS K≪  and also very little ES complex is 
formed, thus [ ] [ ]0 ≈E E . By applying this limit to Equation (2.6), it reduces to 
 
                                         
[ ] [ ] max,    
M
S VS Kt
µ µ∂ = − =
∂
                                      (2.8) 
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Equation (2.8) suggests that the degradation rate of the polymer matrix is 
a function of polymer concentration characterized by parameter µ which should 
be a function of GA concentration and enzyme concentration but independent of 
time if the total enzyme concentration does not change over time. In this in vitro 
experiment, the collagenase concentration was fixed to 373 ng/ml, which mimics 
the synovial fluid of a patient with osteoarthritis.  
Seeing that immobilization of drug molecules in GMS is ascribable to the 
polyionic attraction between them, the liberation rate of immobilized drug is 
assumed to be proportional to the polymer degradation rate or equivalently, the 
immobilizing capacity of polymer substrate σ  is a constant, i.e., iC Sσ= , where 
iC  denotes the concentration of complexed drug; thus, the liberation rate of 
complexed drug can be derived from Equation (2.8): 
 
                                                    
 
0( ) ti iC t C e µ−=                                                 (2.9) 
 
where 0iC  is the initial distribution of complexed drug. 
Note that the relationship between iC  and the concentration of liberalized 
drug sC  is 0s i iC C C= −  and, therefore, 
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Substituting Equation (2.10) into Equation (2.1), the diffusion equation for small 
molecule release from a gelatin microsphere degraded by enzyme becomes 
 
                                   
2  
02
1 ( ) ti
C CDr C e
t r r r
µµ −∂ ∂ ∂ = + ∂ ∂ ∂ 
                                   (2.11) 
 
This model accounts for the drug release mediated by both the initially 
mobile drug and the drug liberated during the polymer-degradation process. The 
nonuniform distributions of initially mobile drug and complexed drug are also 
included in this model via the initial conditions, Equation (2.4) and Equation 
(2.10). 
The relationship between the degradation-related release constant µ  and 
GA concentration is now required for the release to be determined by Equation 
(2.11) with no adjustable parameters. To achieve this, firstly, the parameter µ  
was chosen to minimize the sum of squares of the differences between the 
experimental release data and the solution of Equation (2.11) for GMS cross-
linked with three GA concentrations: 0.125%, 0.375% and 0.875% v/v. 
Subsequently, a numerical equation relating µ  and the GA concentration could 
be established. 
 
2.4     Results and discussion 
Figure 2.2 shows the scanning electron micrographs of the dry GMS 
before and after cross-linking. It is evident that the cross-linked GMS lost their 
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spherical shape when they were dehydrated because of the pores/voids in the 
matrix, but regained spherical shape after water-uptake as seen in Figure 2.2(C). 
The average size of the swollen GMS is 100 µm. Because the actual drug 
release took place in an aqueous media, it was important to retain the uniformity 
of the swollen GMS to be able to predict the release profiles of the active agents 
without the uncertainties associated with the GMS size.  
The swelling ratio of GMS was measured to evaluate the cross-linking 
extent of GMS as shown in Figure 2.3. The swelling ratio reduces as the GA 
concentration increases from 0.125 to 0.25% v/v, but fluctuates after 0.25% v/v. 
The diminution in swelling ratio is likely due to the increase in the density of the 
polymer matrix after cross-linking and the decrease in the free volume for the 
water molecules to penetrate into [53], while the fluctuation might be ascribed to 
higher cross-linking at the surface of GMS limiting the further reduction of 
swelling ratio. The heterogeneous cross-linking within the GMS probably resulted 
from the large GMS size used in this study causing significant concentration 
gradient of GA in the GMS along the diffusion path. It is unlikely that GA 
concentration above 0.25% v/v reacted with all the amino groups in the GMS 
because zeta potential of cross-linked gelatin showed continuous decreases as 
the GA concentration increased, as shown in Figure 2.4. Zeta potential is the 
potential difference between the dispersion medium and the stationary layer of 
fluid attached to the dispersed particles. In other words, it is a measure of the 
overall charge a particle acquires in a specific medium. Thus, the change in the 
charge of gelatin molecules due to cross-linking density could be identified by 
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measuring the zeta potential of homogeneously cross-linked gelatin particles. 
The fall in zeta potential also suggests less attraction between cross-linked basic 
gelatin and the opposite-charged drugs. The fluctuation of swelling ratio might 
also be attributed to hydrophilicity of the cross-linker. The hydrophilicity of the 
gelatin matrix increases as the degree of cross-linking via the GA, a hydrophilic 
compound, increases resulting in a favorable condition for the hydration of GMS. 
With the GA concentrations used in this study, hydrophilicity and density of 
gelatin compensated for each other, giving rise to similar diffusive release 
profiles [54].  
To obtain initial conditions for the proposed model and to elucidate the 
release behavior of the cross-linked GMS as a function of GA concentration, the 
drug distribution in the GMS as a function of GA concentration was investigated. 
Figure 2.5(A) shows the total drug distribution including both mobile drug and 
complexed drug within the GMS, indicating that the initial drug concentration was 
higher at the center for the sample with 0.125% GA but slightly lower for the ones 
with 0.375 and 0.875% GA. This could be attributed to the suppressed drug 
diffusion resulting from the smaller and/or fewer pores of the highly cross-linked 
GMS [46].  
Figure 2.5(B) shows the distributions of the complexed drug which were 
normalized to its percent amount obtained from the release profiles, exhibiting a 
higher concentration at the center of the GMS in all cases. The combination of 
the nonunform distribution of complexed drug within GMS which is higher at the 
surface and lower near the center and the lower attraction between acidic drug 
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and gelatin with the increase of GA as shown in Figure 2.4 suggest an 
inhomogeneous cross-linking with GMS. The extent of inhomogeneous cross-
linking would become more significant at a higher GA concentration because of 
the fact that cross-linking starts from the surface, impeding the inward diffusion of 
GA. 
The initial mobile drug distribution was obtained by subtracting the 
distribution of complexed drug from that of the total drug. The distribution of 
mobile drug was determined by the drug loading mechanisms and the polyionic 
attraction between the drug and the polymer during the drug loading process. 
The release of the mobile drug from the GMS was most likely through simple 
diffusion and contributed to the initial burst in the release profile. Therefore, initial 
burst might be reduced by lowering the amount of drug that is diffusively loaded 
into the GMS. 
The diffusion constants were obtained by solving the diffusion equation 
with the initial mobile drug distribution in a manner to model the first three-day 
drug release profiles by pure diffusion, as described in section 2.3.2. The 
diffusion constants were chosen to minimize the R-squared value. The 
comparison between the experimental data and thus-obtained results predicted 
by the model and the corresponding diffusion constants are shown in Figure 
2.6(A) and (B). A fitting curve using a power function with an R-squared value of 
0.99 is also shown in Figure 2.6(B) which can be used to predict diffusion 
constants from GMS cross-linked with different GA concentrations. Although 
constants for the fitting curve might vary as different drugs are employed 
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because of drug mobility, the trend is likely to remain the same due to the cross-
linking density of gelatin, producing a good estimation in the case of different 
drugs. The diffusion constants are seen to generally decrease with increasing GA 
concentrations. This may be due to higher diffusion barrier resulting from denser 
polymer matrices and reduced free volume accessible by the penetrating water 
molecules because cross-linking agents shorten the polymer chains between the 
cross-links. It is seen in Figure 2.6(A), however, that the drug release rates from 
GMS first fall in the absence of matrix degradation, then rebound when cross-
linking agent concentration exceeds 0.375% v/v. These results may imply that, 
without taking into consideration of other effects, the diffusion constants obtained 
would not be a monotone function of cross-linking agent concentration, which 
was explained in [55] as an inaccuracy resulting from using a single diffusion 
model. However, our work suggests that by incorporating accurate drug 
distribution, diffusivity of a diffusion model depends reciprocally on GA 
concentration, proving the importance of the drug distribution inside the GMS to 
correctly account for the drug release behavior. 
The degradation-related release constant µ  as a function of GA 
concentration that was needed to complete the mathematical model was derived 
by using it as a fitting parameter in Equation (2.11) to calculate the drug release 
from the GMS cross-linked with GA concentrations of 0.125%, 0.375% and 
0.875% v/v while minimizing the sum of squares of deviations from the 
experimental release data with the diffusivities used as before. Figure 2.7 shows 
the model prediction and experimental results. To include the effect of cross-
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linking agent concentration in the model, an empirical exponential decay function 
fit was used to relate the degradation constant to GA concentration, as shown by 
Equation (2.12).  
 
                                      
( 14.29 )0.36(1 0.1exp )GACµ − ×= +                                       (2.12) 
 
where GAC  is the volume percent concentration of GA used to cross-link GMS. 
This dependence was specifically chosen as it gave the best fit to the data (R2> 
0.99). The slower decrease of µ  as GA concentration rises agrees with the 
saturating effect of GA concentration on impeding the release. This phenomenon 
may be elucidated by the cross-linking process facilitated by diffusion and the 
stronger diffusion barrier resulting from higher GA concentration, as described 
earlier. According to the Michaelis-Menten equation (Eqs.(5)-(7)), the 
degradation constant µ  is proportional to the enzyme concentration or its square 
due to anomalous diffusive motion of the enzyme when the gelatin matrix is large 
[56]. Therefore, Equation (2.12) could be modified to make it applicable to other 
enzyme concentrations without further experiments. 
With the degradation-related release constant µ  predicted by Equation 
(2.12), the diffusion-reaction equation, Equation (2.11), was solved to predict the 
release from the GMS treated with 0.25% and 0.625% v/v GA. The comparison 
between model predictions and experimental data is shown in Figure 2.8. A good 
agreement is seen between the model and the experimental data, which may be 
attributed to the fact that the model accounts for the non-uniform drug distribution, 
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the drug-binding ability of the polymer matrix and the polymer degradation rate, 
which are all influenced by the cross-linking agent concentration. The reasons for 
the slight difference between the model prediction and experimental data may be 
as follows: as mentioned earlier, the diffusivities used in the model were 
assumed to be constant within the microsphere throughout the release process. 
It is reasonable, however, to anticipate some variations of diffusion coefficient 
within the microsphere and during the drug release process as the polymer 
matrix degradation progresses. Also, the degradation-related constant µ  and 
diffusion constant D were assumed to be independent of the locations inside the 
GMS whereas the cross-link density is a function of radius. In this model, the 
effect of heterogeneous cross-linking density was considered to affect only the 
ability of the gelatin matrix to bind with the drug and, therefore, the resulting drug 
distribution within the microsphere. However, since the predictions of the present 
model are in reasonable agreement with the experimental data, it may be 
concluded that the radial variation and time-dependence of the degradation-
related constant and diffusion coefficient resulting from heterogeneous cross-
linking and degradation rate are not significant. 
 
  
2.5     Summary 
Monodisperse GMS were fabricated and cross-linked with GA by the E-
PPF method to investigate the effects of GA concentration. It was shown that the 
swelling ratio of GMS decreased as the GA concentration increased, but leveled 
off at higher GA concentrations. The stabilization might be attributed to 
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inhomogeneous cross-linking within the microspheres because of the large size 
of the GMS used in this study or the competing effects such as hydrophilicity and 
cross-linking ability of GA. The zeta potential measurements suggested that the 
higher GA concentration led to lower drug-gelatin complexation. The intraparticle 
distribution patterns of total drug, the addition of mobile and complexed drug, 
indicated that more drug molecules accumulated near the GMS surface as the 
GA concentration increased, probably due to higher diffusion barrier. The 
nonuniform distribution of complexed drug suggested inhomogeneous cross-
linking within GMS which is more evident as GA concentration increases. At 
higher GA concentrations, the GMS surface would be more cross-linked, 
resulting in more resistance to degradation and less gelatin-drug complexation.  
A mathematical model based on drug diffusion and enzymatic degradation 
(Michaelis-Menten kinetics) of polymer matrix as a function of cross-linking agent 
concentration was proposed to describe the release of an acidic drug from cross-
linked basic GMS. The model takes into consideration the initial intraparticle 
distribution of the mobile and complexed drug affected by GA concentrations. 
Diffusion constants are inversely dependent on the GA concentration in spite of 
the fact that the release rate is not a monotone decreasing function of GA 
concentration. A relationship, Equation (2.12), between the degradation-related 
release constant and the GA concentration was obtained which, when 
incorporated into the model, produced results in good agreement with the 
experimental data with no adjustable parameters. It is, therefore, concluded that 
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the present model may serve as a useful tool in predicting drug release from 
GMS. 
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2.6     Figures 
 
         
 
 
Figure 2.1 Scheme of drug release from a gelatin microsphere. 
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Figure 2.2 Gelatin microspheres observed in dry state under SEM before cross-
linking (A), after cross-linking (B) and in wet state under OM (C). The scale bars 
are 30 µm, 30 µm and 50 µm for (A), (B) and (C), respectively.  
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Figure 2.3 Swelling ratios of gelatin microspheres as a function of glutaraldehyde 
concentration. 
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Figure 2.4 Zeta potentials of cross-linked gelatin as a function of glutaraldehyde 
concentration. 
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Figure 2.5 Initial distributions of total drug (A) and complexed drug (B) within the 
gelatin microspheres cross-linked with glutaraldehyde. 
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Figure 2.6 In vitro drug release from the gelatin microspheres as a function of 
glutaraldehyde concentration and their respective model results in the absence of 
enzyme (A) and the corresponding diffusivities obtained via the model (B). 
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Figure 2.7 Model and the experimental results of in vitro drug release from the 
gelatin microspheres cross-linked with glutaraldehyde in the presence of enzyme 
with degradation parameter 1, 0.38 and 0.36, respectively. 
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Figure 2.8 Model predictions and in vitro drug release from the gelatin 
microspheres cross-linked with glutaraldehyde in the presence of enzyme. 
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CHAPTER 3 
GELATIN PARTICLES AS A DRUG CARRIER SYSTEM FOR CANCER 
TARGETING 
 
3.1     Introduction 
Cancer is a class of diseases in which a group of cells multiply beyond the 
normal limits, invade adjacent tissue (invasion) and sometimes spread to other 
locations in the body via the lymphatic or blood system (metastasis). In 2007, the 
American Cancer Society reported 7.6 million cancer deaths globally. 
Chemotherapy is one of the most effective cancer treatment methods by 
impairing cell division, effectively targeting fast-dividing cells; however, off-target 
cancer drug uptaken by benign tissues often causes systemic damage and 
serious side effects. For example, doxorubicin (DXR), one of the most effective 
and widely used anticancer drugs, causes acute adverse effects including 
nausea, vomiting, anorexia and heart damage (cardiotoxicity) [8,9,57] which 
considerably limit the effectiveness of DXR and other chemotherapeutics. 
Therefore the prevention of untargeted therapeutic drug release in the blood 
circulation system is the key to improve outcomes of modern chemotherapy. 
Several strategies have been proposed to target cancer cells, mostly 
based on biodegradable polymeric particles because of their stability [6], 
versatility of surface modification [7] and potential for different drug release 
characteristics [8-10]. Particle drug carriers were reported to be concentrated 
preferentially near tumor sites ascribable to the enhanced permeability and 
retention (EPR) effect of fast-growing tumor vasculature, mitigating off-target 
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drug delivery [58-60]. Though accumulation rate of particles at tumor sites 
increased with particle drug carrier, off-target drug release still existed because 
of the rapid drug release of nanoparticles during circulation. Therefore, potent 
cancer targeting drug carriers should be triggered to release drug only when they 
are at expected tumor sites. 
Particles with surface modification have also been reported for cancer 
targeting based on the recent discovery of over-expression of many molecules in 
cancer patients, including CA125 and human kallikrein 10 for ovarian cancer 
[61,62], prostate-specific antigen (PSA) and cysteine-rich secretory protein-3 for 
prostate cancer [63,64], cytokine colony-stimulating factor-1 (CSF-1) for 
endometrial carcinoma [65], protein 7B2 for medullary carcinoma of the thyroid 
[66], chromogranin A for endocrine and neuroendocrine tumors [67], Cathepsin D 
for breast tumors [68] and many more. One cancer targeting strategy utilizes 
particles conjugated with antibodies that recognize tumor-associated antigens; 
this strategy has shown promising in vivo results as potential diagnostic or 
prognostic of tumors [69]. The in vivo application, however, might be restricted on 
account of weak linkage stability and potential immunogenicity after repeated 
injections [70]. Particles conjugated with proteins to facilitate the recognition of 
tumor-specific antigens as vaccine [71] might suffer from similar obstacles in vivo. 
Due to these limitations, these methods might not be promising in treating cancer. 
A better strategy for cancer targeting drug delivery might be the design of a 
peptide recognizing these over-expressed molecules in cancer sites; this strategy 
has shown promising in vivo results as a potential diagnostic or prognostic of 
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tumors [72] combined with drug release that is triggered only at expected tumor 
sites. 
In this work, we describe surface-modified GMS as a vehicle for the 
targeted delivery of DXR to treat breast malignancy. The drug carrier consists of 
GMS core fabricated via the electric field assisted precision particle fabrication 
(E-PPF) method using an acidic gelatin, loaded with DXR [46,73] and a high-
density peptide layer whose hydrolysis is catalyzed by Cathepsin D, a specific 
protease secreted by the breast cancer cells. Thus, the core is protected from 
general proteolysis, wherein DXR is safely contained, until the peptide shell is 
removed through Cathepsin D-assisted hydrolysis prominent in the proximity of 
breast cancer cells. As the peptide shield is removed, gelatin is exposed to 
general proteases, triggering the release of DXR. As a result, the drug is 
released only in the vicinity of the target cancer cells and its release rate is 
controlled by the protease concentrations. This way, the most effective 
chemotherapy may be achieved with minimal side effects. The E-PPF method 
was modified to reduce the size of GMS fabricated. 
 
3.2     Materials and methods 
3.2.1  Materials 
The starting materials were gelatin type B from porcine skin (225 bloom, 
Sigma–Aldrich,), span 85 (Sigma–Aldrich), hexane (Fluka), acetone (Sigma–
Aldrich), canola oil (Schnucks), 25% glutaraldehyde (GTA) (Sigma–Aldrich), 
sodium hydroxide (Fluka), toluidine blue O (Sigma–Aldrich), 1-ethyl-3-[3-
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dimethylaminopropyl] carbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS) and doxorubicin (DXR) (Sigma–Aldrich), phosphate buffered saline (PBS) 
(Sigma-Aldrich) and dimethyl sulfoxide (DMSO) (Fisher). 
 
3.2.2  Preparation and cross-linking of microspheres 
Gelatin microspheres (GMS) were prepared using the E-PPF method 
described in section 2.2.2. GMS of sub-micron sizes were fabricated through a 
modified E-PPF method in which the electric field applied was increased to 
induce the amount of charge leading to spray of smaller droplets which was 
monitored using video camera. Sample collection was performed as described in 
section 2.2.2.  
The GMS were cross-linked with glutaraldehyde (GA) described in section 
2.2.3 with pH of the solution adjusted to 9 using 0.2M sodium hydroxide. To 
evaluate the effects of the polymer matrix density and the drug-immobilizing 
ability, different GA concentrations were used for cross-linking. 
 
3.2.3  Peptide conjugation 
500 µL of 0.1 M PBS solution, 100 µL of 0.33 M EDC, and 100 µL of 0.5 
mM NHS solution were mixed to form PBS-EDC-NHS solution as catalysts for 
the conjugation [74]. To this mixture, 200 µL of 100 nM peptide which consists of 
a Phe-Phe-Arg-Asp sequence, a Mca fluorophore molecule ((7-
methoxycoumarin-4-yl)acetyl) at the C-terminus, and a darker quencher molecule 
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(dinitrophenyl, abbreviated as Dnp) near the N-terminus (synthesized by BioMol) 
and drug-loaded GMS were added and stirred overnight. The resulting mixture 
was centrifuged and washed with DMSO to collect peptide-conjugated GMS.  
3.2.4  Drug impregnation  
Cross-linked GMS were impregnated with a model drug, TBO or DXR, by 
adding an aqueous solution in a ratio of 5 µl/mg GMS and cured for 24 hrs at 
room temperature. Loading efficiency of TBO as a function of pH of drug medium 
and cross-linking of GMS was determined by measuring absorbance of TBO with 
spectrometer (Gary-5G) at wavelength of 630 nm. 
 
3.2.5  Characterization 
Morphology and uniformity of GMS were examined through SEM (Hitachi 
4700) after platinum coating. Zeta potentials of the cross-linked gelatin were 
determined using dynamic light scattering technique (NICOMP 380 ZLS Particle 
Sizer), and swelling ratios of GMS cross-linked with different GA concentrations 
were measured as described in section 2.2.5.  
 
3.2.6  In vitro drug release profiles 
The in vitro release study of DXR from the drug-loaded GMS with and 
without the peptide surface coating was performed in the presence of Cathepsin 
D enzyme, MCF7 culture media, 3T3 culture media or Hela culture media. Drug 
release was assessed by directly sampling the supernatant and measuring the 
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fluorescence emission from DXR molecules which is measured using the 
microplate reader (excitation of 470 nm and emission of 585 nm). Protease-, 
DNA-, and RNA-free water (Fisher Scientific) was used for the measurement. 
 
3.2.7  In vitro chemotherapy on cancer cells 
MCF7 (ATCC), 3T3, and Hela cells were cultured in petri dishes and let 
grow till nearly confluent. Drug-loaded GMS conjugated with peptides were 
added into the cell cultures media. Optical images were taken every two hours 
for 10 hours. Trypsin-EDTA (ATCC) was used to trypsinize the cells for viable 
cell counting. Cell counting was done using hemocytometer (Neubauer) with 
trypan blue stain (Sigma-Aldrich) for cell viability tests. 
 
3.3     Results and discussion  
The SEM and optical images in Figure 3.1(A) and (B), respectively, 
illustrate that the GMS fabricated via the E-PPF method are spherical and 
uniform in size: 30 ± 2 (dry) and 65 (wet) µm in diameter. The confocal laser 
scanning microscopy image in Figure 3.1(C) shows the distribution of the 
impregnated DXR in the GMS, measured at 580 nm. DXR (pKa=8.2) is expected 
to interact electrostatically with the gelatin matrix, whose IEP was measured to 
be 5 as shown in Figure 3.2(A).  
The DXR molecules immobilized by the gelatin would be delivered to the 
targeted cancer site without being released while the unbound ‘free’ molecules 
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are released systemically via diffusion. Therefore, maximization of the drug 
bound to the GMS matrix, i.e. the drug loading efficiency, is crucial in the 
mitigation of the off-target release. To study the factors affecting the loading 
efficiency, TBO was chosen as a model drug with a pKa value of 7.9, close to 
that of DXR, 8.2, and impregnated into the GMS cross-linked with 0.625 % v/v 
GA. Figure 3.2 (B) shows the loading efficiency measured as a function of pH of 
the impregnation medium, exhibiting that the efficiency was improved generally 
as the pH increased. In a basic environment, the negative charge of the gelatin 
would be enhanced by the deprotonation of its carboxyl groups, which was 
supported by the zeta potential decrease with pH (Figure 3.2(A)). On the other 
hand, the protonation of TBO would be promoted in the acidic media of pH lower 
than the pKa of the drug [27]. Therefore, the increase in the loading efficiency 
observed in the basic media indicated that the former effect was more dominant 
than the latter on promoting the electrostatic interactions between the gelatin and 
TBO. 
The effect of GMS cross-linking on the drug loading efficiency was 
investigated using the GA concentrations of 0.125 – 0.875% v/v. Figure 3.3(A) 
shows that the loading efficiency increased with GA concentration until it reached 
0.625% but decreased afterwards. The acidity of gelatin would increase with GA 
concentration, i.e., cross-linking, due to the consumption of its amino groups in 
the cross-linking process. This was confirmed by the zeta potential of the gelatin 
measured as a function of GA concentration (Figure 3.3(B)), leading to the 
increase in the loading efficiency. However, at a GA concentration of 0.875%, the 
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loading efficiency was observed to decrease, indicating that the acidity was not 
the only factor affecting the efficiency. With the cross-linking, the density of the 
gelatin matrix increases, which would cause more hindrance for inward diffusion 
of the drug during the loading process due to the decreased water content of the 
GMS. Figure 3.3(C) shows the decreased swelling ratio, i.e., the water content, 
of the GMS as a function of GA concentration. The matrix density may not be a 
dominant factor affecting the drug diffusion when it is low, but becomes 
significant when high, off-setting the electrostatic effect. This could account for 
the decreased loading efficiency observed for the GMS cross-linked with 0.875% 
GA.  
Drug release profiles of DXR from GMS with and without peptide coating 
incubated in pure buffer solution, purified Cathepsin D solution, purified 
collagenase 1A solution, secretion with culture media of MCF7 human breast 
cancer cells, 3T3 mouse fibroblast cells and Hela cells were expressed as 
fluorescence intensity of DXR (Figure 3.4) which is assumed to be proportional to 
drug concentration. More drug is released from GMS than from peptide coated 
GMS when incubated with and without collagenase, which is a common protease 
in the body facilitating hydrolysis of gelatin. This observation suggests that the 
peptide coating layer hinders the diffusive release and degradation of gelatin. 
The drug release from GMS with peptide coating is prohibited in most of the 
above cases except for the purified Cathepsin D solution and MCF7 breast 
cancer cell secretion proving the targeting function of the peptide coating layer. 
The drug release difference between these two cases might be explained by the 
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different concentrations of Cathepsin D secreted by MCF7 cells and the purified 
Cathepsin D or other proteases secreted by MCF7 cells. For instance, it has 
been known that MCF7 cells also secrete into culture media collagenase [75] 
assisting the hydrolysis of GMS, which likely contributes to the increased release 
of DXR compared to the case of Cathepsin D. The slight fluorescence increase in 
the case of 3T3 cells might also be attributed to similar secretion of collagenase 
by 3T3 [76]. The enhancement of drug release ascribable to collagenase-
assisted hydrolysis of gelatin leading to the dissociation of the drug carriers was 
also observed in Figure 3.4 showing increasing fluorescence intensity from both 
coated and uncoated GMS cultured with collagenase 1A. Drug release from the 
coated GMS, however, is still much suppressed compared to the nude GMS with 
or without the presence of collagenase 1A. This evidence once again proved that 
the peptide layer on the drug carrier particle surface dramatically diminishes the 
non-specific drug release. 
Figure 3.5 shows the number of viable cells for three cancer cell lines at 
every two hours after the addition of the peptide coated GMS loaded with DXR. 
As shown in Figure 3.5, the number of both 3T3 fibroblast and Hela cells 
increases because of the cell proliferation, indicating negligible cytotoxicity to 
these two non-targeted cells secreting no aspartic protease (e.g. Cathepsin D). 
The lower proliferation rate of 3T3 viable cells after 6 hours might be attributed to 
the mild DXR release as a consequence of collagenase secreted by 3T3 cells. 
On the contrary, the number of MCF7 breast cancer cells dropped dramatically to 
13% in 10 hours. This result proves that the peptide coating enables the high 
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specificity of the particle drug delivery system to targeted cancer biomarkers and 
associated tumor cells. 
Figures 3.4 and 3.5 were obtained by Dr. Munima Haque under the 
supervision of Professor Logan Liu who collaborated with us on this work. 
The concept of utilization of peptide-coated GMS as a drug carrier 
targeting breast malignancy has been demonstrated to be effective in vitro. For 
particles to be injected intravenously, they should be smaller than the diameter of 
capillaries, 10 µm, to avoid infarction [77]. Such a size limit might be less 
stringent for gelatin particles because of their elasticity. The E-PPF method 
utilizes vibration waves on a liquid jet to produce uniform droplets (Figure 3.6(A)) 
and employs the electric field so that droplets are charged and Coulomb 
repulsion between droplets prevents recombination (Figure 3.6(B)). The droplet 
size is mainly restricted by the jet diameter and thus-produced GMS are usually 
larger than 50 µm (wet). With the increase of electric field came the increase of 
induced charge on droplets and the breakup of droplets because the Coulomb 
repulsion force overcame the surface tension and viscosity of the solution [78] as 
seen in Figure 3.6(C). This method utilized generation of uniform microdroplets to 
avoid the formation of Taylor cone before spraying, which was difficult because 
of high conductivity of the water as the solvent. Figure 3.7 shows the SEM image 
of gelatin particles of 50 µm in diameter produced with an applied voltage of 5 kV, 
demonstrating the modified E-PPF method could be employed to fabricate 
particles suitable for intravenous injection. 
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3.4     Summary 
Peptide-coated GMS are developed as a cancer targeting drug carrier. 
Release of drug complexed to the gelatin matrix is triggered by the biomarker 
protease enzyme Cathepsin D secreted by breast cancer cells and their 
extracellular matrix. Drug loading efficiency was optimized by controlling the 
cross-linker concentration and pH of drug solution. With the peptide-coated GMS, 
the specificity of cancer chemotherapeutic drug delivery is expected to be 
improved significantly and the adverse side-effects are to be reduced due to the 
mitigated off-target drug release. The E-PPF method could be modified to 
produce GMS much smaller than the jet diameter, suitable for in vivo application, 
via the applied electric field.  
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3.5     Figures  
 
                                          
 
 
Figure 3.1 Gelatin microspheres observed in dry state under SEM before cross-
linking (A), after cross-linking in wet state under OM (B) and after doxorubicin 
loading under CLSM (C). Scale bars are 20, 50, and 50 µm for (A), (B), and (C), 
respectively. 
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Figure 3.2 Drug loading efficiencies in gelatin microspheres (A) and zeta 
potentials of gelatin as a function of pH (B).  
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Figure 3.3 Drug loading efficiencies (A), zeta potentials (B) and swelling ratios as 
a function of glutaraldehyde concentration.  
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Figure 3.4 Fluorescence intensity of released drug from the gelatin microspheres 
in various incubation conditions. Abbreviations used in the figures: pGMS for 
peptide coated gelatin microspheres; CatD, Cathepsin D; Col. 1A, collagenase 
1A.  
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Figure 3.5 Viability of MCF7 human breast cancer, human Hela and 3T3 mouse 
fibroblast cells after exposure to the peptide-coated gelatin microspheres loaded 
with doxorubicin. 
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                          (A)                                 (B)                                (C) 
 
 
Figure 3.6 Gelatin droplets of 100 µm generated via E-PPF method with applied 
electric potentials of 0 V (A), 200 V (B) and 2.5 kV (C). 
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Figure 3.7 SEM image of dry gelatin particles. 
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 CHAPTER 4 
FABRICATION, CHARACTERIZATION AND SORTING OF ALGINATE 
MICROSPHERES/MICROCAPSULES FOR CELL ENCAPSULATION 
 
4.1     Introduction 
Encapsulation of living cells in a semi-permeable system has been 
developed over the past decades as a strategy for tissue and organ replacement 
and long-term controlled release of therapeutic agents. In 1980, Lim et al. 
reported the first successful implantation of microencapsulated islet of 
Langerhans which led to numerous efforts at achieving xenotransplantation 
without immunosupression [79]. Later, encapsulation of hepatocyte cells was 
investigated as a supportive device, either to allow liver regeneration upon acute 
liver failure or extend liver function until a transplant is available [14,80]. In 
addition to primary cells, encapsulation of genetically engineered cells secreting 
therapeutic proteins has also been proposed to target various diseases and 
malignancies while delivery of genes producing proteins via transcription and 
translation has not demonstrated definitive clinical value at present [81]. Table 
4.1 shows an overview of some encapsulated cells for protein delivery [81].  
In 1997, Wang et al. thoroughly screened polymers for cell encapsulation 
based on cytotoxicity and cell attachment properties [82]. Among the materials 
tested, alginate showed the lowest cytotoxicity and best cell attachment. Other 
materials such as poly(ethylene glycol) (PEG) [83], hyaluronic acid [84,85], 
chitosan [86], agarose [87], and synthetic polymers have also been tested for cell 
encapsulation. However, alginate has been and still is the most important 
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biomaterial for cell encapsulation. Alginates are natural polysaccharides 
extracted from seaweed consisting of homopolymeric regions of β-D-mannuronic 
acid (M-blocks) and α-L-guluronic acid (G–blocks) and interspersed with regions 
of MG blocks. The constituents of alginate affect greatly the properties for the 
purpose of cell encapsulation [88-95]. The ratio and arrangement of mannuronic 
acid and guluronic acid affect the dimension stability and gel strength greatly 
because of their different binding efficiency to divalent ions such as Ca2+, Ba2+, 
and Sr2+, which are the most common cross-linking agents for alginate [94]. Also, 
studies indicate a high content of M-blocks in alginate (more than 85%) can 
provoke undesired immune reactions [96,97]. 
Cell encapsulation using alginate microcapsules is usually performed by 
dispersing the alginate solution drops containing cells into an aqueous solution 
containing cross-linking agents. The whole process is carried out in aqueous 
solution which is favorable to keep cells alive. Various methods have been 
developed to produce drops including dripping [91], coaxial air jet [98], 
electrostatic dripping [99], mechanical cutting [100] and jet break-up [101]. 
Despite remarkable progress in the cell encapsulation technology, several 
obstacles still need to be overcome for viable clinical applications. The main 
considerations for the encapsulation technology include the following: (1) uniform 
microcapsules of controlled sizes for different applications, (2) high production 
rates to minimize processing time and therefore stress to cells, (3) no air bubbles 
trapped inside microcapsules which might limit diffusion and weaken long-term 
gel stability [102], (4) handling of high viscosity alginate solutions to ensure 
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immunoisolation and (5) low number of void microcapsules, namely, high 
efficiency of cell encapsulation. 
To fulfill such requirements, the precision particle fabrication (PPF) 
method was adopted and modified for cell encapsulation, which was developed 
to fabricate uniform microspheres and microcapsules of poly(lactide-coglycolide), 
ethylcellulose, chitosan and other polymers. In this chapter, a novel cell 
encapsulation technology for fabricating alginate microspheres/microcapsules of 
precisely controlled sizes of 150-600 µm in diameter is described. Properties of 
thus-fabricated alginate microspheres/microcapsules and viability of 
encapsulated cells were examined. The feasibility of sorting void capsules from 
the ones containing cells was demonstrated by employing a detection and 
electric deflection system. 
 
4.2     Materials and methods 
4.2.1  Materials 
Sodium alginate used in this study was purchased from Sigma-Aldrich 
(intrinsic viscosity of 250 cp, 2% (25oC)) or obtained from laminaria hyperborean 
(SF120, FMC Biopolymer, Drammen, Norway). Mannitol (VWR), calcium chloride 
(Fluka), barium chloride (Aldrich), sodium chloride (Fluka), blue dextran (Sigma), 
murexide (Fluka) and rhodamine B (Sigma) were purchased. 
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4.2.2  Preparation of alginate microspheres and cell encapsulation 
Sodium alginate (2-3.5% w/v) was dissolved in purified water and filtered 
through 0.22 µm-pore filter paper for sterilization. Sodium chloride (0.15M) or 
mannitol (0.3M) was co-dissolved in the alginate solution to maintain osmotic 
pressures of human pancreatic islet cells. In some cases, mouse fibroblast cells 
or bovine liver tissues were dispersed in alginate solution for encapsulation. The 
protocol for encapsulation of human pancreatic islet cells was adopted from the 
work of Norwegian University of Science and Technology [103]. 
A coaxial dual-nozzle was used to produce a cell-containing jet 
surrounded by polymer solution which is disrupted into uniform droplets by a 
piezoelectric transducer controlled by a frequency generator. The droplets 
generated in the air were observed via video camera and recorder to determine 
the droplet size and collected in an aqueous gelling solution (CaCl2 or BaCl2) with 
stirring. The spheres were left in the gelling solution for less than 5 minutes to 
minimize stress to cells. The distance between the nozzle and the collection bath 
was optimized to produce uniform alginate microspheres while other fabrication 
parameters were fixed. The diameter of the outer nozzle opening and the 
vibration frequency were also varied to fabricate microspheres/microcapsules of 
different sizes. The resulting microspheres were filtered with mesh and washed 
several times with purified water or culture media. For some cases, oil or a blue 
dextran solution was fed through the inner nozzle during the fabrication of 
alginate microcapsules to observe the material passing through the inner nozzle. 
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4.2.3  Characterization 
More than 150 microspheres fabricated under different conditions were 
examined and visualized by optical microscopy to determine the size and 
uniformity of each sample. The distribution of alginate molecules within the 
microsphere was examined by staining them with Rhodamine B. Alginate 
microspheres fabricated were dispersed in 0.5% w/v Rhodamine B solution and 
washed with DI water after 3 hours to remove the excess dye molecules. 
Rhodamine B bound to alginate was observed via a confocal laser scanning 
microscope (CLSM, Olympus Fluoview FV 300 Laser Scanning Biologic 
Microscope). 
The penetration of the cross-linking agent, calcium ion, through alginate 
was examined using murexide as a complexometric indicator. A drop of alginate 
solution with 100 µM murexide was placed into a Petri dish containing calcium 
chloride solution, resulting in an alginate sphere with a diameter about 3 mm 
while the whole process was observed under optical microscope. Three different 
concentrations of sodium alginate and calcium chloride solutions were used for 
this study: [Alginate]: 2, 3 and 4% w/v, and [CaCl2]: 50, 100 and 200 mM. The 
hardened alginate spheres were observed under optical microscope and images 
were taken at designed time intervals.  
 
4.2.4  Cell viability  
Viability of pancreatic islet cells before and after encapsulation was 
assessed according to a dual fluorescent staining technique, fluorescein 
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diacetate (FDA)/ propidium iodide (PI) [104]. FDA, a nonfluorescent derivative of 
fluorescein, can penetrate the cell membrane and be deacetylated by nonspecific 
esterase resulting in accumulation of fluorescein within cells as a sign of viability 
when only the nuclei of membrane-compromised cells will be bound by PI 
fluorescing red, a sign of cell death. Stock solution of FDA (5 mg/ml in acetone) 
and PI (20 µg/ml in Dulbecco’s phosphate buffered saline (DPBS)) were stored in 
the dark at 4 oC. Staining was performed with FDA which was freshly prepared 
by adding the stock solution to 10 ml of DPBS to a final concentration of 20 µg/ml 
and PI stock solution. Pancreatic islet cells before and after encapsulation were 
washed with Hank’s balanced salt solution (HBSS) and re-suspended in 1 ml of 
HBSS before staining. Cells were stained by adding 0.1 ml of FDA working 
solution and 0.03 ml of PI stock solution and examined under a fluorescence 
microscope (Olympus IX81) 3 minutes after the addition of the dyes. The ratio of 
cell number to dye was approximately 2×106 cells to 2 µg of FDA plus 0.6 µg of 
PI. 
 
4.2.5  Sorting scheme 
Sorting of void and cell-containing microcapsules can increase cell 
encapsulation efficiency by eliminating void ones. Sorting of cells and 
chromosomes has been achieved via electrostatic deflection of charged droplets, 
similar to the method used for ink-jet printers [105]. Despite the advances in this 
technology, the popularity of this sorting technique is limited due to the expensive 
detection method involving laser sources which might also cause damage to cells. 
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In this study, optical microscopic imaging and digital image processing were 
employed to detect cells in the microcapsules generated from the encapsulator. 
Figure 4.1 shows the illustrative scheme of the sorting function equipped 
in the encapsulator. The encapsulator generates uniform droplets to place the 
point at which droplets break off from the main stream (breakoff point) at a fixed 
distance downstream from the observation point. During the time a cell traverses 
the observation point and reaches the breakoff point (drop delay), the 
measurement result is sent to the sort logic control and then the decision signal 
is sent to the droplet charging circuit. Charge can be applied to droplets via direct 
charging or indirectly by putting a charging ring at the breakoff point. The droplet 
stream containing charged or uncharged droplets passes through the electric 
field between the two metal plates to which high voltages of opposite polarities 
have been applied. Sorting can be achieved by deflecting the charged droplets 
out of the main stream.  
To estimate the transverse distance a charged droplet traveled, average 
induced charge on droplets was measured using a Fluke 87V multimeter. The 
droplets were caught in a metallic plate connected to a grounded 10 MΩ resistor, 
and the electric current passing the resistor could be measured. The theoretical 
value of induced charge on the droplet is derived as follows. Assuming the 
grounded jet is surrounded by a cylindrical electrode with electric potential 
r
V  and 
radius cR , the grounded liquid jet of radius jr  can be approximated by solving the 
Laplace equation (neglecting boundary effect due to finite length of the cylinder) 
and expressed as 
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where r  is the distance from the center of the metal ring on this plane. For 
simplicity, it is assumed that such electric field surrounds the jet of the 
wavelength λ , which forms one droplet. By applying Gauss’s law, we can derive 
the induced charge on each droplet as 
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The wavelength λ , solution velocity and frequency are related by the following 
equation: 
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Substituting Equation (4.3) into Equation (4.2),  
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Droplets are slower relative to the jet velocity because of surface tension 
pulling the liquid back toward the nozzle. The theoretical values of induced 
charge calculated with jet and droplet velocity were compared with the 
experimental data. 
The electric field intensity E  is regarded as uniform distribution in the 
region between two parallel plates if fringing effect is neglected. The intensity can 
be expressed as the voltage difference on the two plates, 2 eV , divided by the 
distance between them, D . The horizontal acceleration of a droplet with charge 
q  due to the electric field E  can be expressed as 
 
                                                   
2 eqVqEa
m mD
= =                                              (4.5) 
 
where m  is the mass of a droplet. With the acceleration and traveling time, the 
horizontal distance one charge droplet travels away from the stream could be 
estimated as Equation (4.6). 
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Cell detection is achieved optically with image processing technology 
without laser or fluorescent dye introduced. Two sorting logic schemes were 
discussed in this section. The first method is traditional detection based on the 
fact that encapsulated particles or cells hinder the light from shinning through the 
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transparent drops or microspheres, causing lower light intensity at the location 
where the cells or particles locate (light intensity method). An intensity threshold 
might be tuned to indicate the presence of cells if light intensity was found to be 
lower than the threshold. The second detection method was based on the fact 
that the presence of particles would cause sharp intensity variation at the edge of 
cells or particles (edge detection method). Large light intensity gradient occurs at 
the periphery of the cell aggregates or in the interface of the alginate solution and 
air. If we define the location where the gradient is greater than a gradient 
threshold (GT) as an edge pixel, the presence of cells would increase the 
number of edge pixels, which can be used to identify the encapsulation of cells. 
In this study, the GT was empirically determined using the alginate microcapsule 
containing an ethyl cellulose particle as a model which would be used in 
determination of cell encapsulation in alginate microcapsules. Optical images of 
more than 50 alginate microcapsules were examined with the two proposed 
methods to determine the detection accuracy.  
 
4.3     Results and discussion  
Alginate capsules were fabricated by feeding an alginate solution to the 
nozzle forming a smooth jet which was later broken into uniform alginate droplets 
via vibration waves during the fabrication. Due to the fast solidification reaction of 
the alginate, the distance between the nozzle and the collection bath containing 
the cross-linking agent, the collecting distance, is a crucial parameter for the 
capsule fabrication. Figure 4.2 shows optical microscopic images of the alginate 
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spheres collected at three different collecting distances of 3.5, 5 and 10 cm as 
shown in Figure 4.2 (A-C) ([alginate]: 2 % w/v and [CaCl2]: 50 mM) 
demonstrating the effect of the collecting distance on the geometry or uniformity 
of the final product. Figure 4.2 (D) shows the possible fluid conditions based on 
the morphology of alginate samples. The phenomenon might be explained as 
follows. The applied vibration destabilizes the stream, making it break into 
droplets at a critical point (the break-off point) where the mechanical wave 
applied overcomes surface tension and viscosity. If the collecting distance is 
shorter than the distance between the nozzle and the break-off point, which is 
affected by jet velocity, frequency of vibration, viscosity and surface tension of 
the solution, then no distinct alginate microspheres are collected (Figure 4.2(A)). 
Once detached from the jet, uniform droplets form resulting in uniform alginate 
spheres after cross-linking (Figure 4.2(B)). The velocity of droplets is slower 
relative to the jet velocity when separated from the jet, as surface tension and 
viscosity of the solution pull the fluid back to the nozzle. Also thin filaments 
between the droplets might occur for a viscoelastic solution, resulting in different 
velocities for neighboring droplets. These phenomena could cause droplet 
coalescence and non-uniform alginate beads (Figure 4.2(C)). 
By varying jet diameter and vibration frequency, alginate microspheres of 
different sizes (150-600 µm) were fabricated. Flow rates were adjusted to form a 
laminar jet to prevent undesired disturbances from breaking the jet. Laminar jet 
can be characterized by a small Reynolds number, usually bellow 2300 [105,106], 
as shown in Equation (4.7) where ρ  is the density of the fluid (kg/m3), Q  
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volumetric flow rate (m3/s), η  dynamic viscosity (poise) and dD  the jet diameter 
(m). 
  
4Re
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ρ
piη
=                                                        (4.7) 
 
Figure 4.3 shows the size distribution of the microcapsules of various mean sizes. 
Conditions for controlling the capsule size are favorable since the size 
requirement for encapsulating different cells varies [19,107]. For example, 
Dufrane et al. showed that pig islets in alginate microcapsules with a diameter of 
635 µm survived up to six months after transplantation without 
immunosuppression [18]. On the other hand, hepatocyte cells in alginate 
microcapsules larger than 400 µm might not remain viable due to the limited 
diffusion of oxygen and nutrients [19]. Figure 4.3(B) shows the relationship 
between the droplet and microcapsule sizes ([alginate]: 2.4% w/v and [CaCl2]: 50 
mM). During the solidification process, the significant size shrinkage from 
droplets to microspheres suggests that dense packing of the alginate molecule 
chains occurs, which agrees with the theory that alginate solidification is not a 
point cross-linking but rather a junction-zone. A recent X-ray diffraction study 
indicated that the junction zone in calcium alginate gel might be described by 3/1 
or 2/1 helical conformation (also known as egg-box model) [95,108]. 
Cross-linking of alginate is required to provide mechanical stability and 
immunoprotection for cell encapsulation, but the cross-linking process might be 
adverse to cell viability. Therefore, the processing time should be minimized. To 
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determine the processing time for sufficient cross-linking of alginate, mureixde, a 
metal ion chelator, was used to visualize the diffusion of the calcium ion during 
the gelation process. The color of the murexide molecules changed from purple 
to light-orange when the chelation with calcium ions in the alginate drops 
occurred. The boundary between these two distinct colors was observed by 
optical microscopy (Figure 4.4(A)) to obtain the rates of the calcium ions diffusing 
into the drops of 2, 3 and 4% w/v alginate solution in 50, 100 and 200 mM CaCl2 
bath (Figure 4.4(B)). The diffusion of calcium ions was hindered as the alginate 
concentration increased because of the increased diffusion barrier and was 
facilitated as the concentration of the calcium ion increased.  
Figure 4.5 shows the non-uniform distribution of the alginate molecules in 
the microsphere prepared using a 2% w/v alginate solution and a 50 mM CaCl2 
bath, suggesting that the gelation process involves not only the motion of the 
calcium ions but also that of the alginate molecules. Rhodamine B, a cationic 
fluorescent dye forming a polyionic complex with alginate, provided an 
approximate distribution of alginate within the microspheres. The migration of 
alginate is likely due to the attractive force between the alginate and calcium ions 
since, initially, the polymer distributed uniformly within the droplet. 
To visualize the material in the inner tube, canola oil or blue dextran in water 
was fed into the inner tube to be encapsulated in alginate spheres. Oil 
encapsulated in the core of the alginate capsule was spherical (Figure 4.6(A)) 
owing to the interfacial tension between oil and water. Without the interface 
tension, the blue dextran solution encapsulated in the capsule core was not 
  69 
spherical (Figure 4.6(B)). However, the blue dextran core enclosed in the 
alginate microcapsules suggested that the alginate capsules produced via this 
method would prevent cells from protrusion. 
Microencapsulation of various cells has been studied for different 
therapeutic applications [109]. Mouse fibroblast, bovine liver cells and human 
islet cells were encapsulated in alginate microcapsules via the present method to 
demonstrate the feasibility of encapsulating diverse cells (Figure 4.7). Cell 
viability assay with FDA/PI showed no significant difference in viability (85%) 
before and after the encapsulation, which suggested the encapsulation did not 
imperil cells. 
The feasibility of cell sorting during encapsulation could be accomplished 
via electric deflection. To determine the distance droplets traveled during 
deflection, the induced charge on droplets (pF) was measured and compared 
with theoretical prediction calculated by Equation (4.4) as shown in Figure 4.8. 
The theoretical prediction is 1.47 times higher than the experimental result if the 
velocity of the jet is used in the calculation, while the prediction with droplet 
velocity is close to the experimental result. The discrepancy between the jet and 
droplet velocity arises from surface tension and velocity of the solution as 
described before. With the induced charge on droplets, the distance droplets 
traveled can be estimated based on Equation (4.6). 
The core of the cell sorting system would be the detection of cell-
containing and void capsules. Figure 4.9 shows the optical images of alginate 
capsules used for testing the accuracy of the detection methods. The detection 
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was achieved via the edge detection method, which was compared with the 
traditional light intensity method. Figure 4.10 shows the detection accuracy of the 
light intensity method as a function of light intensity threshold in which cells are 
assumed to be detected when there is light with intensity below the preset 
intensity threshold. The accuracy of the detection of cell-containing 
microcapsules increases as the intensity threshold increases while that of void 
microcapsules decreases. Intensity threshold of 0.2 gives optimal accuracy of 
70% and 95% for detecting encapsulated and empty capsules.  
The edge detection method for cell detection requires a reference of 
gradient threshold and was obtained prior to the experiment using alginate 
microcapsules containing ethyl cellulose particles as a model. The optical images 
and the location of edge pixels with the corresponding gradient threshold were 
shown in Figure 4.11, indicating that the number of edge pixels increases as GT 
decreases. In the edge detection method, we defined presence of a cell to be 
when the number of edge pixels was greater than a specific threshold value 
because edge pixels could be introduced by the periphery of the alginate 
microdroplet. By presetting the GT as 0.4 and proper edge pixel number 1800, 
detection accuracies for cell-containing and void capsules were 100% and 95%, 
respectively, more accurate than the light contract method. Note that the choice 
of GT for edge pixel number depends greatly on the resolution of the optical 
image and the size of alginate microcapsules. The edge detection is superior 
because the intensity of the light source might not affect the results since only the 
gradient of light intensity has been taken into account for the detection.  
  71 
 
4.4     Summary 
Uniformly sized alginate microspheres/microcapsules with diameters of 
150-600 µm were fabricated for encapsulating cells using the modified PPF 
method. Non-uniform distribution of the alginate molecules within the 
microspheres, denser at the bead periphery, and significant size shrinkage from 
alginate microdroplets to microspheres suggested polymer rearrangements occur 
during the gelling process, supporting the junction-zone model for the alginate 
cross-linking process. Cell viability assay of human pancreatic islet cells with 
FDA/PI shows similar viability before and after alginate encapsulation, which 
suggests that this technology is suitable for cell encapsulation. A sorting scheme 
which consists of optical detection method and electric deflection can be 
annexed to the encapsulator to increase the encapsulation efficiency. The edge 
detection method is found to be 15% more accurate in cell detection than the 
light intensity threshold method. 
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4.5     Figures and table 
 
 
                     
 
Figure 4.1 A scheme of encapsulator and sorting apparatus. 
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Figure 4.2 Optical microscopic images of alginate samples collected at collecting 
region of (A), (B) and (C). The scale bars are 200 µm. 
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Figure 4.3 Size distributions of alginate microspheres of different sizes (A) and 
the droplet size vs. sphere sizes from a 2% alginate solution gelled in a 50mM 
calcium chloride solution (B). 
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Figure 4.4 Optical images (A) and diffusion speed (B) of calcium ions through 
alginate droplets. The scale bars are 200 µm. 
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Figure 4.5 A confocal laser scanning microscopic image of an alginate sphere 
stained with Rhodamine B. The scale bar is 200 µm. 
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Figure 4.6 Optical microscopic images of alginate spheres encapsulating canola 
oil (A) and blue dextran (B). The scale bar is 200 µm. 
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Figure 4.7 Optical images of alginate microcapsules containing mouse fibroblast 
cells (A), bovine liver tissues (B) and human islet cells (C). A fluorescence optical 
image of encapsulated islet cells treated with FDA/PI (D). 
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Figure 4.8 Comparison between theoretical and experimental values of induced 
charge on droplets. 
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Figure 4.9 Optical images of alginate microcapsules with (A) and without (B) islet 
cells. The scale bars are 500 µm. 
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Figure 4.10 Detection accuracy as a function of intensity threshold via light 
intensity method. 
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Figure 4.11 Optical images of alginate microcapsules containing ethyl cellulose 
particles before (A) and after edge detection process (B-E) to show location of 
edge pixels. 
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Table 4.1 Overview of some potent applications of encapsulated cells. 
Disease Cell line  Protein 
Anyotrophic lateral sclerosis BHK CNTF 
Diabetes Langerhans islets Insulin 
Gliomas 293 cells Endostain 
Huntington's disease BHK CNTF 
Pancreas cancer 293 CYP2B1 
Parkinson's disease PC 12 Dopamine  
Chronic pain Adrenal cells from calves Catecholamines 
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 CHAPTER 5 
CONCLUSIONS AND FUTURE WORK 
 
With increasing availability of potent/delicate drugs such as biomolecules or 
living cells that are being considered as a therapy, comes the need for 
developing methods for encapsulating such therapeutics to maintain their 
functionality/ viability or to increase their delivery specificity. Hydrogel is an 
excellent candidate as an encapsulation material because of its biocompatibility. 
On the other hand, fabrication of hydrogel particles may be limited due to the 
properties of hydrogel and therapeutics and the particle size. In this thesis work, 
we investigated various applications of uniform hydrogel particles fabricated via 
precision particle fabrication (PPF) method and its modifications, and we studied 
the drug release mechanism using a newly formulated model which may help 
improve the design of drug delivery vehicles.  
The gelatin microspheres of precisely controlled size and size distribution, 
fabricated by the electric field assisted precise particle fabrication (E-PPF) 
method, allowed a detailed analysis of drug release as a function of 
glutaraldehyde without the uncertainties related to nonuniformity particle size. 
Zeta potential measurement showed that higher cross-linking of gelatin led to 
lower complexation between gelatin and acidic drug. The intraparticle drug 
distribution patterns indicated that higher complexation of acidic drug took place 
in the microsphere center as the glutaraldehyde concentration increased, 
suggesting different affinity to acidic drug within the gelatin microsphere. At 
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higher glutaraldehyde concentrations, the microsphere surface would be more 
cross-linked, resulting in higher resistance to degradation and lower gelatin-drug 
complex. Due to the inhomogeneous cross-linking, the effect of GA concentration 
on the drug release profile was not linear. The results from this analysis were 
subsequently used to formulate a release model based on the reaction-diffusion 
and Michaelis-Menten kinetics. This model accurately predicted the drug release, 
and was therefore used as a design tool for drug release once the drug diffusion 
constant and initial drug distribution have been obtained in advance. 
For targeted delivery of chemotherapeutics to cancer sites, the gelatin 
particles were coated with a peptide, eliminating adverse effects resulting from 
systemic distribution of toxic chemicals. The results of the release study and 
chemotherapy on cancer cells confirmed that the drug delivery vehicle may 
substantially enhance the efficacy of chemotherapy which, in turn, would reduce 
the adverse effect of chemotherapy ascribable to systemic distribution of 
chemotherapeutics. The drug release from the peptide-coated gelatin particles 
was triggered by Cathepsin D secreted by the breast cancer cells. Maximization 
of drug loading could mitigate off-target drug release, and the precise control of 
the particle size enabled us to obtain the factors affecting the drug loading and 
drug release, which is not possible with non-uniform particles produced via the 
conventional methods. Optimal drug loading efficiency could be achieved via 
basic drug solution (pH=11) and moderate glutaraldehyde concentration 
(0.0625%) ascribable to the dissociation of the drug in the base and the 
competition between lower swelling ratio and higher binding between drug and 
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gelatin as glutaraldehyde concentration increases. To further the study in vivo, 
the electric field strength in the E-PPF method was increased to allow for 
fabrication of gelatin particles of submicron or nano scale through break-up of the 
uniform microdroplets. The resulting particles were smaller than 10 µm. A further 
study is to follow by investigating the optimal particle size for in vivo study 
depending on the clearance rate of particles, release profiles and enhanced 
permeability and retention effect at the tumor sites. Furthermore, by designing 
the appropriate peptide sequence specific to different cancer biomarkers, this 
concept could be expanded to other malignancies. 
The PPF method was also modified to encapsulate living cells while 
maintaining their viability. With this method, alginate microcapsules of different 
sizes (150-600 µm) were fabricated to allow for encapsulation of various cells, 
which may advance the development of cell-based therapy. Formation of alginate 
microspheres/microcapsules from alginate microdroplets involved the motion of 
both alginate molecules and calcium ions. The significant size shrinkage from 
alginate microdroplets to microspheres indicated a junction-zone mode of the 
cross-linking process. A sorting scheme, combining optical detection and electric 
deflection, was developed to eliminate empty capsules and reduce the net 
volume of capsules for clinical transplantation. The edge detection method is 
considered to be more accurate in cell detection compared to the traditional light 
intensity threshold method. 
In conclusion, we have demonstrated versatile application of uniform 
hydrogel particles in controlled drug delivery and tissue engineering fabricated 
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via PPF method. The uniform particles of controlled size allowed a more accurate 
understanding of the drug release mechanism. Drug functionality and cell viability 
could be maintained after the fabrication/encapsulation process. Continued study 
with the hydrogel microparticles should lead to more efficacious therapy based 
on biomolecules and potent therapeutics. 
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